Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FRESENIUS SE & CO. KGAA

(FRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fresenius : Conference Call Q2 2021 (PDF, 2.71 MB)

07/30/2021 | 08:50am EDT

Conference Call │ Q2/21 Results

Bad Homburg, 30 July 2021

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing.

Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Q2/21 Results, 30 July 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

2

Agenda

01

Key messages

02

03

04

Strategic update

Financial review

Outlook FY/21

Q2/21

Q2/21 Results, 30 July 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

3

Key messages Q2/21

Very strong performance

Rebounding elective

Cost & efficiency program:

Guidance raised despite

with dynamic sales and net

procedures in all relevant

First measures implemented;

expected challenges in

income growth

markets

Net income savings >€100

H2/21

million p.a. in 2023 expected

Expected continued COVID

Recovery in Emerging

Recovering elective

Back to sales and EBIT

impact; significantly

Markets more than offsets

treatments in Germany;

growth

reduced patient excess

ongoing headwinds in North

outstanding growth in Spain

mortality rates

America

over weak prior-year comp

Q2/21 Results, 30 July 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

4

Agenda

01

Key messages

02

Strategic update

03

04

Financial review

Outlook FY/21

Q2/21

Q2/21 Results, 30 July 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Fresenius SE & Co. KGaA published this content on 30 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 12:48:02 UTC.


ę Publicnow 2021
All news about FRESENIUS SE & CO. KGAA
09/23European ADRs Move Sharply Higher in Thursday Trading
MT
09/23FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 40, Section 1 of the W..
DJ
09/22FRESENIUS SE : Berenberg reaffirms its Buy rating
MD
09/22FRESENIUS SE : Gets a Buy rating from Goldman Sachs
MD
09/21FRESENIUS SE : DZ Bank reaffirms its Buy rating
MD
09/20FMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Sell rating from Jefferies
MD
09/20PRESS RELEASE : Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific O..
DJ
09/17FRESENIUS : Bank of America – Global Healthcare Conference (PDF, 5.96 MB)
PU
09/17FRESENIUS MEDICAL CARE : Selects JMS Co. as Distributor of Home Dialysis Systems in Japan
MT
09/17FMC FRESENIUS MEDICAL CARE AG & CO K : Sell rating from Jefferies
MD
More news
Analyst Recommendations on FRESENIUS SE & CO. KGAA
More recommendations
Financials
Sales 2021 37 433 M 43 872 M 43 872 M
Net income 2021 1 818 M 2 131 M 2 131 M
Net Debt 2021 22 787 M 26 706 M 26 706 M
P/E ratio 2021 12,6x
Yield 2021 2,09%
Capitalization 22 947 M 26 870 M 26 893 M
EV / Sales 2021 1,22x
EV / Sales 2022 1,10x
Nbr of Employees 312 734
Free-Float 73,1%
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 41,12 €
Average target price 49,88 €
Spread / Average Target 21,3%
EPS Revisions
Managers and Directors
Stephan Sturm President & Chief Executive Officer
Rachel Clare Empey Chief Financial Officer
Wolfgang Kirsch Chairman-Supervisory Board
Sebastian Biedenkopf Legal, Compliance & Human Resources Director
Klaus-Peter MŘller Independent Member-Supervisory Board